Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
News|Articles|October 21, 2015
Catalent Names President of Clinical Supply Services Business
Author(s)Pharmaceutical Technology Editors
Wetteny Joseph has been appointed as president of Catalent’s Clinical Supply Services.
Advertisement
Wetteny Joseph has been appointed as president, clinical supply services for Catalent Pharma Solutions, the company announced on Oct. 22, 2015.
Joseph joined Catalent in 2008 as corporate controller, and in 2012, was charged with leading the finance function for the company’s modified release technologies business unit. in 2013, he was promoted to vice president of finance for Catalent’s Development and Clinical Services division, which included the Clinical Supply Services business unit.
Before joining Catalent, Joseph held senior financial positions at HD Supply, including CFO of a $1.2 billion business unit. He also served as corporate controller at Hughes Supply and spent six years at PricewaterhouseCoopers as an auditor, and as a strategic financial advisor across a variety of industries.
Joseph earned Master’s and bachelor’s degrees in accounting from Florida Atlantic University.
Source:
Advertisement
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
What the Olanzapine Depot Approval Means for CMC Teams
3
Complying with International Pharmacopoeias
4
Q&A: Patient-Centric Drug Development Should Start at Product Definition
5